-
-
-
-
-
-
-
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
-
-
-
-
-
-
-
Exelixis (EXEL) Tops Q2 EPS by 11c, provides guidance
-
-
-
-
-
-
-
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
-
-
-
-
-
-
-
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
-
-
-
-
-
-
-
Leerink Partners Reiterates Market Perform Rating on Exelixis (EXEL)
-
-
-
-
-
-
-
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Exelixis (EXEL) Reports Prelim FY23 Results, Issues 2024 Guidance
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

